Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry
- PMID: 16828308
- DOI: 10.1016/j.ymeth.2006.05.004
Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry
Abstract
There has been a recent explosion in research concerning novel bioactive sphingolipids (SPLs) such as ceramide (Cer), sphingosine (Sph) and sphingosine 1-phosphate (Sph-1P) that necessitates development of accurate and user-friendly methodology for analyzing and quantitating the endogenous levels of these molecules. ESI/MS/MS methodology provides a universal tool used for detecting and monitoring changes in SPL levels and composition from biological materials. Simultaneous ESI/MS/MS analysis of sphingoid bases (SBs), sphingoid base 1-phosphates (SB-1Ps), Cers and sphingomyelins (SMs) is performed on a Thermo Finnigan TSQ 7000 triple quadrupole mass spectrometer operating in a multiple reaction monitoring (MRM) positive ionization mode. Biological materials (cells, tissues or physiological fluids) are fortified with internal standards (ISs), extracted into a one-phase neutral organic solvent system, and analyzed by a Surveyor/TSQ 7000 LC/MS system. Qualitative analysis of SPLs is performed by a Parent Ion scan of a common fragment ion characteristic for a particular class of SPLs. Quantitative analysis is based on calibration curves generated by spiking an artificial matrix with known amounts of target synthetic standards and an equal amount of IS. The calibration curves are constructed by plotting the peak area ratios of analyte to the respective IS against concentration using a linear regression model. This robust analytical procedure can determine the composition of endogenous sphingolipids (ESPLs) in varied biological materials and achieve a detection limit at 1 pmol or lower level. This and related methodology are already defining unexpected specialization and specificity in the metabolism and function of distinct subspecies of individual bioactive SPLs.
Similar articles
-
Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry.Methods Mol Biol. 2009;579:443-67. doi: 10.1007/978-1-60761-322-0_22. Methods Mol Biol. 2009. PMID: 19763489
-
Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics.Methods Enzymol. 2007;432:83-115. doi: 10.1016/S0076-6879(07)32004-1. Methods Enzymol. 2007. PMID: 17954214
-
Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry.Methods. 2005 Jun;36(2):207-24. doi: 10.1016/j.ymeth.2005.01.009. Methods. 2005. PMID: 15894491
-
Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).Adv Exp Med Biol. 2010;688:46-59. doi: 10.1007/978-1-4419-6741-1_3. Adv Exp Med Biol. 2010. PMID: 20919645 Review.
-
Analysis of macrolide antibiotics, using liquid chromatography-mass spectrometry, in food, biological and environmental matrices.Mass Spectrom Rev. 2009 Jan-Feb;28(1):50-92. doi: 10.1002/mas.20189. Mass Spectrom Rev. 2009. PMID: 18785191 Review.
Cited by
-
Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia.BMC Cancer. 2024 Apr 4;24(1):414. doi: 10.1186/s12885-024-12104-0. BMC Cancer. 2024. PMID: 38570770 Free PMC article.
-
Lipidomics reveals the significance and mechanism of the cellular ceramide metabolism for rotavirus replication.J Virol. 2024 Apr 16;98(4):e0006424. doi: 10.1128/jvi.00064-24. Epub 2024 Mar 15. J Virol. 2024. PMID: 38488360
-
ReTimeML: a retention time predictor that supports the LC-MS/MS analysis of sphingolipids.Sci Rep. 2024 Feb 22;14(1):4375. doi: 10.1038/s41598-024-53860-0. Sci Rep. 2024. PMID: 38388524 Free PMC article.
-
Gene therapy with AAV9-SGPL1 in an animal model of lung fibrosis.J Pathol. 2024 May;263(1):22-31. doi: 10.1002/path.6256. Epub 2024 Feb 9. J Pathol. 2024. PMID: 38332723
-
Developing new ceramide analogs against non-small cell lung cancer (NSCLC).Am J Cancer Res. 2024 Jan 15;14(1):86-96. doi: 10.62347/AOGP2839. eCollection 2024. Am J Cancer Res. 2024. PMID: 38323290 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources